Estrogen Promotes Chemotherapeutic Drug Resistance by a Mechanism Involving Bcl-2 Proto-Oncogene Expression in Human Breast Cancer Cells

Cancer Research

Volumn 55, Issue 17, 1995, Pages 3902-3907

  Teixeira, Christine ^a   Pratt, M A Christine ^a   Reed, John C ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTO ONCOGENE;

APOPTOSIS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE; ESTRADIOL; ESTROGENS; HUMAN; NEOPLASMS, HORMONE-DEPENDENT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0029157380     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Lippman, M. E. Endocrine responsive cancers of man. In: R. H. Williams (ed.), Textbook of Endocrinology, pp. 1309–1326. Philadelphia: W. B. Saunders Co., 1985.
2. McGuire, W. L., Carbone, P. P., and Vollman, E. P. (eds.) Estrogen receptors in human breast cancer. New York: Raven Press, 1975.
3. Kyprianou, N., English, H. F., Davidson, N. E., and Isaacs, J. T. Programmed cell death during regression of the MCF-7 human breast cancer cell following estrogen ablation. Cancer Res., 57: 162–166, 1991.
4. Lippman, M. E., and Dickson, R. B. Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog. (Basel), 45: 383–440, 1989.
5. Kenney, N. K., Saeki, T., Gottardis, M., Kim, N., Garcia-Morales, P., Martin, M. B., Normanno, N., Ciardello, F., Day, A., Cutler, M. L., and Solomon, D. S. Expression of transforming growth factor a antisense mRNA inhibits the estrogen-induced proliferation of estrogen-responsive human breast cancer cells. J. Cell. Physiol., 756: 497–514, 1993.
6. Slamon, D. J., Godolphin, W., Jones, L. A., Hott, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707–712, 1989.
7. Berthois, Y., Dong, X. F., and Martin, P. M. Regulation of epidermal growth factor receptor by estrogen and antiestrogen in human breast cancer cell line, MCF-7. Biochem. Biophys. Res. Commun., 759: 126–131, 1989.
8. Dubik, D., and Shui, R. P. C. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene, 7: 1587–1594, 1992.
9. Raff, M. C. Social controls on cell survival and cell death. Nature (Lond.), 356: 398–400, 1992.
10. Nunez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., and Kors-meyer, S. J. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoetic cell lines. J. Immunol., 144: 3602–3610,1990.
11. Tsujimoto, Y. Stress resistance conferred by high level Bcl-2a protein in human B lymphoblastoid cell. Oncogene, 4: 1331–1336, 1989.
12. Wagner, A. J., Small, M. B., and Hay, N. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol. Cell. Biol., 13: 2432–2440, 1993.
13. Bissonnette, R. P., Echeverri, F., Mahboubi, A., and Green, D. R. Apoptotic cell death induced by c-myc is inhibited by Bcl-2. Nature (Lond.), 359: 552–556, 1992.
14. Fanidi, A., Harvington, F. A., and Evan, G. I. Cooperative interaction between c-myc and bcl-2 protooncogenes. Nature (Lond.), 359: 554–556, 1992.
15. Chiou, S., Rao, L., and White, E. Bcl-2 blocks p53-dependent apoptosis. Mol. Cell. Biol., 14: 2556–2563, 1994.
16. Walton, M. I., Whysong, D., O′Connor, P. M., Hockenbery, D., Korsmeyer, S. J., and Kohn, K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and campothecin-induced apoptosis. Cancer Res., 53: 1853–1861, 1993.
17. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151–157, 1993.
18. Dole, M., Nunez, G., Merchant, A. K., Maybaum, J., Rode, C. K., Bloch, C. A., and Castle, V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res., 54: 3253–3259, 1994.
19. Hanada, M., Krajewski, S., Tanaka, S., Cazals-Hatem, D., Spengler, B. A., Ross, R. A., Biedler, J. L., and Reed, J. C. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res., 53: 4978–4986, 1993.
20. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151–163, 1993.
21. Maniatis, T., Fritsch, E. F., and Sambrook, J. Molecular Cloning: A Laboratory Manual. Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
22. Ruffray, C., and Rougeon, F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur. J. Biochem., 107: 303–314, 1980.
23. Reed, J. C., Meister, L., Tanaka, S., Cuddy, M., Yum, S., Geyer, C., and Pleasure, D. Differential expression of bcl2 protooncogene in neuroblastoma and other tumor cell lines of neural origin. Cancer Res., 57: 6529–6538, 1991.
24. Tsujimoto, Y., and Croce, C. M. Analysis of the structure, transcripts and protein products of Bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA, 83: 5214–5218, 1986.
25. Hockenbery, D. M., Oltvai, Z. N., Yin, X. M., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241–251,1993.
26. Kane, D. J., Sarafin, T. A., Auton, S., Hahn, H., Gralla, F. B., Valentine, J. C., Ord, T., and Bredesen, D. E. Bcl-2 inhibition of neural cell death: decreased generation of reactive oxygen species. Science (Washington DC) 262: 1274–1276, 1993.
27. Bafy, G., Miyashita, T., Williamson, J. R., and Reed, J. C. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoetic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J. Biol. Chem., 268: 6511–6519, 1993.
28. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609–619, 1993.
29. Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (Lond.), 359: 321–323, 1994.
30. Leek, R. D., Kaklamanis, L., Pezzella, F., Gatter, K. C., and Harris, A. L. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer, 69: 135–139, 1994.
31. Seto, M., Jaeger, U., Hockett, R. D., Graninger, W., Bennett, S., Goldman, P., and Korsmeyer, S. J. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-lg fusion gene in lymphoma. EMBO J., 7: 123–131, 1988.
32. Krishnan, V., Wang, X., and Safe, S. Estrogen receptor-Spl complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J. Biol. Chem., 269: 15912–15917, 1994.
33. Sukovich, D. A., Mukherjee, R., and Benfield, P. A. A novel, cell-type specific mechanism for estrogen receptor-mediated gene activation in the absence of an estrogen-responsive element. Mol. Cell. Biol., 14: 7134–7143, 1994.
34. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799–1805, 1994.
35. Miyashita, T., Harigai, M., Hanada, M., and Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131–3135, 1994.
36. Haldar, S., Negrini, M., Monne, M., Sabbioni, S., and Croce, C. M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54: 2095–2097, 1994.
37. Moll, U. M., Riou, G., and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262–7266, 1992.
38. Suzuki, K., Ono, T., and Takahashi, K. Inhibition of DNA synthesis by TGF-/3 coincides with inhibition of phosphorylation and cytoplasmic translocation of p53 protein. Biochem. Biophys. Res. Commun., 183: 1175–1183, 1992.
39. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121–139, 1992.
40. Dive, C., and Wyllie, A. H. Apoptosis and cancer chemotherapy. In: J. A. Hickman and T. R. Tritton (eds.), Cancer Chemotherapy, pp. 21–56. Oxford, United Kingdom: BlackweU Publishers, 1993.
41. Webster, N. J. G., Green, S., Jin, J. R., and Chambon, P. The hormone binding domain of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell, 54: 199–207, 1988.
42. Tormey, D. C., Gray, R., Abeloff, M. D., Roseman, D. L., Gilchrist, K. W., Baryka, H. J., Stoff, P., and Falkson, G. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an eastern cooperative oncology group trial. J. Clin. Oncol., 10: 1848–1856, 1992.
43. Boccardo, F., Rubagotti, A., Amoroso, A., Sismondi, P., Genta, F., Nenci, I., Piffanelli, A., Farris, A., Castagnetta, L., Traina, A., Cappellini, M., Pacini, P., Sassi, M., Malacarne, P., Donati, D., Mustacchi, G., Galletto, L., Schieppati, G., Villa, E., Bolognesi, A., and Gallo, L. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. Eur. J. Cancer., 28: 673–680, 1992.